Corrigendum to "The potential molecular pathways of astragaloside-IV in colorectal cancer: A systematic review" [Biomed. Pharmacother. 167 (2023) 115625
机构:[1]Department of Health Management & Institute of Health Management, Sichuan Provincial People’s Hospital, Chengdu, PR China四川省人民医院[2]School of Medicine, University of Electronic Science and Technology of China, Chengdu, PR China[3]Faculty of Nursing, Xi’an Jiaotong University, Xi’an, PR China[4]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, PR China
The authors regret “there is a mistake in the molecular formula of Astragaloside-IV (AS-IV) in introduction section. It should be corrected from (C14H68O14) to (C41H68O14).” The authors would like to apologise for any inconvenience caused.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|2 区医学
小类|1 区药学2 区医学:研究与实验
最新[2023]版:
大类|2 区医学
小类|1 区药学2 区医学:研究与实验
第一作者:
第一作者机构:[1]Department of Health Management & Institute of Health Management, Sichuan Provincial People’s Hospital, Chengdu, PR China[2]School of Medicine, University of Electronic Science and Technology of China, Chengdu, PR China
通讯作者:
通讯机构:[1]Department of Health Management & Institute of Health Management, Sichuan Provincial People’s Hospital, Chengdu, PR China[2]School of Medicine, University of Electronic Science and Technology of China, Chengdu, PR China[4]Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, PR China
推荐引用方式(GB/T 7714):
Ziyang Tang,Xirong Hu,Chongming An,et al.Corrigendum to "The potential molecular pathways of astragaloside-IV in colorectal cancer: A systematic review" [Biomed. Pharmacother. 167 (2023) 115625[J].BIOMEDICINE & PHARMACOTHERAPY.2023,115787.doi:10.1016/j.biopha.2023.115787.
APA:
Ziyang Tang,Xirong Hu,Chongming An&Tingxin Li.(2023).Corrigendum to "The potential molecular pathways of astragaloside-IV in colorectal cancer: A systematic review" [Biomed. Pharmacother. 167 (2023) 115625.BIOMEDICINE & PHARMACOTHERAPY,,
MLA:
Ziyang Tang,et al."Corrigendum to "The potential molecular pathways of astragaloside-IV in colorectal cancer: A systematic review" [Biomed. Pharmacother. 167 (2023) 115625".BIOMEDICINE & PHARMACOTHERAPY .(2023):115787